Comparing Daiichi Sankyo (DSNKY) and The Competition

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Daiichi Sankyo to similar companies based on the strength of its profitability, valuation, dividends, earnings, analyst recommendations, risk and institutional ownership.

Volatility & Risk

Daiichi Sankyo has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, Daiichi Sankyo’s rivals have a beta of -4.20, indicating that their average stock price is 520% less volatile than the S&P 500.

Insider and Institutional Ownership

32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Daiichi Sankyo and its rivals’ net margins, return on equity and return on assets.

Dividends

Daiichi Sankyo pays an annual dividend of $0.34 per share and has a dividend yield of 1.9%. Daiichi Sankyo pays out 34.7% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 49.4% of their earnings in the form of a dividend.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Daiichi Sankyo and its rivals, as provided by MarketBeat.com.

As a group, “Pharmaceuticals” companies have a potential upside of 25.50%. Given Daiichi Sankyo’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Daiichi Sankyo has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Daiichi Sankyo and its rivals revenue, earnings per share and valuation.

Daiichi Sankyo has higher revenue, but lower earnings than its rivals. Daiichi Sankyo is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Daiichi Sankyo rivals beat Daiichi Sankyo on 9 of the 15 factors compared.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.